Compare Barclays PLC (BCS) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs Intuitive Surgical, Inc. — how do they compare? Barclays PLC trades at $27.87 (market cap $94.10B), while Intuitive Surgical, Inc. trades at $400.52 (market cap $138.97B). The key difference: Intuitive Surgical, Inc. is the larger of the two by market cap, and Barclays PLC pays a 2.18% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| BCS | ISRG | |
|---|---|---|
Market Cap | $94.10B | $138.97B |
Sector | Financials | Health |
52-Week High | $28.56 | $592.85 |
52-Week Low | $19.36 | $332.02 |
Dividend Yield | 2.18% | — |
Enterprise Value | — | $133.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $27.93, down 0.89% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.90 exceeding the $0.89 estimate. Revenue grew to $29.14 billion in 2025, with a net income margin of 25.51%. Analyst consensus is 68% buy, though recent news highlights a securities class action investigation.
The outlook for BCS is positive given earnings momentum and a low P/E of 10.73, but risks include the legal investigation and rising costs noted in Q2 2026. Investment opportunity lies in valuation discount and dividend yield, while sentiment is mixed due to near-term headwinds.
Intuitive Surgical (ISRG) trades at $378.81, up 1.36% with strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows bullish technical signals despite premium valuations (P/E 43.44, P/S 12.35), supported by robust revenue growth reaching $10.06B in 2025 and expanding profit margins of 28.45%. Recent news highlights da Vinci 5 adoption driving procedure growth beyond urology.
Outlook remains positive with 68% analyst buy ratings and $519.05 price target suggesting 37% upside. Key risks include competitive pressure from Medtronic/J&J robots and potential U.S. procedure softness. The combination of durable demand and innovation pipeline supports long-term growth potential for MedTech investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
